menu
    • menu

    Company profile for Inozyme Pharma

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Inozyme Pharma is a biotechnology company developing new medicines to treat rare, debilitating, and life-threatening calcification disorders for which there are no adequate treatment options. We are focused on devastating and debilitating rare diseases that largely impact infants, children, and young adults. In certain rare, life-threatening, and devastating genetic disorders, PPi levels are below the normal levels. These low ...
    Inozyme Pharma is a biotechnology company developing new medicines to treat rare, debilitating, and life-threatening calcification disorders for which there are no adequate treatment options. We are focused on devastating and debilitating rare diseases that largely impact infants, children, and young adults. In certain rare, life-threatening, and devastating genetic disorders, PPi levels are below the normal levels. These low levels can lead to over-mineralization of soft tissues and/or under-mineralization of bone, which cause damage and disease to bones, arteries, and organs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Inozyme PharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    321 Summer Street, Floor 4 Boston, MA 02210
    Telephone
    Telephone
    +1 (857) 330-4340
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.inozyme.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/inozyme/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BioMarin Completes Inozyme Acquisition
    BioMarin Completes Inozyme Acquisition

    01 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biomarin-announces-completion-of-acquisition-of-inozyme-302495683.html

    PR NEWSWIRE
    01 Jul 2025
    Share Share
    BioMarin Completes Acquisition of Inozyme Pharma for $270M
    BioMarin Completes Acquisition of Inozyme Pharma for $270M

    01 Jul 2025

    // CONTRACTPHARMA

    https://www.contractpharma.com/breaking-news/biomarin-completes-acquisition-of-inozyme-pharma-for-270m/

    CONTRACTPHARMA
    01 Jul 2025
    Share Share
    Inozyme Pharma postpones 2025 Annual Stockholders Meeting
    Inozyme Pharma postpones 2025 Annual Stockholders Meeting

    20 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/20/3102952/0/en/Inozyme-Pharma-Inc-Announces-Postponement-of-2025-Annual-Meeting-of-Stockholders.html

    GLOBENEWSWIRE
    20 Jun 2025
    Share Share
    BioMarin Inks $270M Inozyme buyout, phase 3 prospect
    BioMarin Inks $270M Inozyme buyout, phase 3 prospect

    17 May 2025

    // PRESS RELEASE

    https://investors.biomarin.com/news/news-details/2025/BioMarin-Strengthens-Enzyme-Therapy-Business-with-Acquisition-of-Inozyme-Pharma/default.aspx

    PRESS RELEASE
    17 May 2025
    Share Share
    Inozyme Pharma Reports Q1 2025 Financial Results & Highlights
    Inozyme Pharma Reports Q1 2025 Financial Results & Highlights

    14 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/14/3081039/0/en/Inozyme-Pharma-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Highlights.html

    GLOBENEWSWIRE
    14 May 2025
    Share Share
    Inozyme Pharma Announces JBMR Plus Publication on ENPP1 Deficiency
    Inozyme Pharma Announces JBMR Plus Publication on ENPP1 Deficiency

    10 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/10/3059238/0/en/Inozyme-Pharma-Announces-JBMR-Plus-Publication-Demonstrating-Real-World-Impact-of-ENPP1-Deficiency.html

    GLOBENEWSWIRE
    10 Apr 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search